Will Dukarb Plus next month rise as Boryung’s savior?
By Lee, Tak-Sun | translator Alice Kang
22.05.30 06:18:20
가나다라
0
In preparation of entry of generics after expiry of Kanarb and Dukarb patents
3-drug combo market increase fourfold over the past 5 years, shows high potential for success
▲Picture from the Dukarb Plus launch symposium that was held on the 25th at Shilla Hotel Seoul
A product that uses the antihypertensive ingredient fimasartan (Kanarb) that Boryung Pharmaceutical developed will be released next month. The product, Dukarb Plus, is a fixed 3-drug combination of fimasartan, amlodipine, and hydrochlorothiazide. Dukarb Plus will be listed for insurance benefit as of June 1st. The release of Dukarb Plus has been receiving attention due to the imminent expiration of the substance patent for Kanarb. Boryung Pharmaceutical is hoping Dukarb Plus will act as a savior against the flood of generics set to enter with Kanarb’s patent expiry.
3 doses of Dukarb Plus that were approved on March 31st are set to receive insurance benefits only 3 months since their
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)